Market revenue in 2022 | USD 12,259.1 million |
Market revenue in 2030 | USD 18,327.8 million |
Growth rate | 5.2% (CAGR from 2022 to 2030) |
Largest segment | Non-opioid |
Fastest growing segment | Compound Medication |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Opioid, Non-opioid, Compound Medication |
Key market players worldwide | Bayer AG, Assertio Holdings Inc, Johnson & Johnson, GSK PLC, AbbVie Inc, Novartis AG ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to analgesics market will help companies and investors design strategic landscapes.
Non-opioid was the largest segment with a revenue share of 50.94% in 2022. Horizon Databook has segmented the North America analgesics market based on opioid, non-opioid, compound medication covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America analgesics market, including forecasts for subscribers. This continent databook contains high-level insights into North America analgesics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account